All In Biotech

Drug Trial Radar · NCT03579836

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

May 14, 2018

Primary completion

Nov 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
BeyondBio Inc.Industry
Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

Conditions

  • Locally Advanced or Metastatic Pancreatic Cancer

Interventions

  • BEY1107Drug

    Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.

  • GemcitabineCombination product

    Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD & Safety assessment (Phase I)Time frame: 0
  2. DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II)Time frame: 0

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yonsei University Health System Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.